Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Radiation Oncology
Would you recommend hypofractionated treatment for early stage, bilateral breast cancers?
Assume each primary meets ASTRO 2018 guidelines
Answer from: Radiation Oncologist at Community Practice
yes as i don't see any reason and have done multiple times
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
Agreed, key is to ensure fields are set up to prevent any potential overlap
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
Yes, check for overlap. Otherwise, there is no glaring contraindication.
Sign in or Register to read more
4383
4395
4397
Related Questions
In a patient with otherwise favorable DCIS and a focally positive margin who refuses reexcision, is APBI an appropriate treatment option?
What pentoxifylline and vitamin E dose do you typically use for both the prevention and treatment of radiation-associated fibrosis after breast RT?
With the more recent validation studies, have you integrated the use of DCISion RT into your practice?
How would you manage a patient with a negative axillary ultrasound but no sentinel lymph node evaluation at the time of lumpectomy for early-stage breast cancer?
How do you reconcile the differences between 2022 ABS APBI recommendations and 2023 ASTRO APBI recommendations?
How would you approach a patient that did not have preoperative axillary imaging and was found to have macromets on sentinel node biopsy, and on radiation planning scan has abnormal appearing nodes?
Is it acceptable to give hypofractionated breast radiation in a patient who is being treated for rheumatoid arthritis with Actemra, methotrexate and leucovorin?
In what clinical scenario, if any, would you consider APBI appropriate treatment for a patient with triple-negative breast cancer?
For path CR after neoadjuvant chemotherapy in breast cancer with sentinel node (2-3 nodes) negative but >4 nodes positive on initial PET, do you boost the nodes not assessed by sentinel node?
For a patient receiving postmastectomy IMRT to chest wall with expander and regional nodes including IMN, what constraint would you use for dose to the contralateral chest wall/implant if the patient also had a mastectomy and reconstruction on that side?